| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/13/2001 | WO2001065949A1 Treatment of infection in animals |
| 09/13/2001 | WO2001045712A8 Combinations of medicaments for treating viral diseases |
| 09/13/2001 | WO2001030759A3 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028993A3 Tyrosine kinase inhibitors |
| 09/13/2001 | WO2001028992A3 New oxabispidine compounds useful in the treatment of cardiac arrhythmias |
| 09/13/2001 | WO2001028498A3 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 09/13/2001 | WO2001028497A3 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 09/13/2001 | WO2001028492A3 Polyanhydrides with biologically active degradation products |
| 09/13/2001 | WO2001028338A3 Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
| 09/13/2001 | WO2001026666A3 Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba |
| 09/13/2001 | WO2001026635A3 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 09/13/2001 | WO2001019542A8 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/13/2001 | WO2001016288A3 Dna encoding the human serine protease c-e |
| 09/13/2001 | WO2001015671A3 Flushable disposable polymeric products |
| 09/13/2001 | WO2001015593A3 Compositions for reducing vascular plaque formation and methods of using same |
| 09/13/2001 | WO2001013906A3 Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| 09/13/2001 | WO2001009138A3 Chemokine receptor antagonists and methods of use therefor |
| 09/13/2001 | WO2001009000B1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 09/13/2001 | WO2001005805A3 Novel c-19-halogen-substituted, 5-substituted, 5-substituted or 6,10 carbocyclically condensed steroids of the androst-9(11)-ene-series, methods for the production and use thereof |
| 09/13/2001 | WO2001005387A3 Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic and menthol for topical application, uses and process for the preparation thereof |
| 09/13/2001 | WO2001004282A3 Replication-competent anti-cancer vectors |
| 09/13/2001 | WO2000072836A8 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide |
| 09/13/2001 | WO2000059886A3 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors |
| 09/13/2001 | WO2000056302A9 Vanadium (iv) complexes containing catacholate ligand and having spermicidal activity |
| 09/13/2001 | WO2000053191A3 Modulation of skeletal muscle precursor cell activation |
| 09/13/2001 | WO2000044443A9 Intra-pericardial delivery of anti-microtubule agents |
| 09/13/2001 | WO2000034780A8 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 09/13/2001 | WO1997042968A3 Administration of histamine for therapeutic purposes |
| 09/13/2001 | WO1997037631A3 Chemotherapeutic veterinary drug containing oxytetracycline, sulfadimidine and neomycin |
| 09/13/2001 | WO1997014683A3 Phenanthridine derivatives, methods of producing them and medicaments containing phenanthridine derivatives |
| 09/13/2001 | WO1997009039A3 Composition comprising vitamin f |
| 09/13/2001 | WO1996040038A3 Treatment of anemia with procaine compositions |
| 09/13/2001 | US20010021850 Spine distraction implant |
| 09/13/2001 | US20010021791 Cyclopropyl phenyl ketone compound |
| 09/13/2001 | US20010021777 Indane or dihydroindole derivatives |
| 09/13/2001 | US20010021775 Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa |
| 09/13/2001 | US20010021772 Vascular endothelial growth factor |
| 09/13/2001 | US20010021723 Histochrome and its therapeutic use in ophthalmology |
| 09/13/2001 | US20010021722 Pharmaceutical compositions comprising monoamine oxidase b inhibitors |
| 09/13/2001 | US20010021720 Synergistic mixture of docletaxel and phosphodiesterase inhibitor |
| 09/13/2001 | US20010021719 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents |
| 09/13/2001 | US20010021717 Hydroxylation activated prodrugs |
| 09/13/2001 | US20010021716 Using agonist of nicotinergic acetylcholine receptors |
| 09/13/2001 | US20010021715 Gastrointestinal disorders |
| 09/13/2001 | US20010021712 Antihistamines, antiallergens, brochodilator agents and antispasmodic agents |
| 09/13/2001 | US20010021708 Acylurea compound containing imidazolidine ring |
| 09/13/2001 | US20010021707 Composition |
| 09/13/2001 | US20010021706 Administering a beta-lactam antibiotic with a beta-lactamase inhibiting compound such as benzhydryl 2-beta-(chloroacetoxy-methyl)-6-((z)-(tert-butoxycarbonyl)methylene) penicillinate to treat beta-lactam resistant bacterial infections |
| 09/13/2001 | US20010021705 Inhibition of human bone loss |
| 09/13/2001 | US20010021704 Active compounds with cytostatic activity, biological electron acceptors, and pharmaceutically customary additives |
| 09/13/2001 | US20010021698 Methods and kits for removing, treating, or preventing lice with driable pedicul ostatic agents |
| 09/13/2001 | US20010021694 Treating bulimia and eating disorders, stimulating cholecystokinin, protein powder with glycomacropeptide or casein, fatty acid, fiber |
| 09/13/2001 | US20010021693 Non-aqueous or oily injection formulation obtainable by in-situ preparation and stabilization of the free, unstable base of valnemulin; treating infectious diseases in livestock and domestic animals; storage stability |
| 09/13/2001 | US20010021532 Using cells comprising promoters having an AP1 site linked to a reporter gene so compounds capable of blocking or inducing expression of the reporter gene can be identified |
| 09/13/2001 | US20010021526 Immortal rho degrees cell line; undifferentiated cells for drug screening; alzheimers, huntington's disease, myoclonic epilepsy lactic acidosis and stroke (MELAS); myoclonic epilepsy ragged red fiber (MERRF) |
| 09/13/2001 | US20010021517 An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with macrophase migration inhibiatory factor (MIF) gene selected from dirofilaria immitis MIF gene and Onchocerca volvulus MIF gene |
| 09/13/2001 | US20010021510 Materials and methods for detection and treatment of immune system dysfunctions |
| 09/13/2001 | US20010021507 Renal nuclear matrix protein able to differentiate cancerous renal cell from normal renal cells; useful for diagnosis and producing treatment for cell proliferative disorders of the kidney |
| 09/13/2001 | US20010021506 The functionalized silicon compound containing one or more derivatizable functional group selected from the group consisting of hydroxyl, amino, amido, carboxyl, thio, halo and sulfonate, and one or more acativated silicon group |
| 09/13/2001 | US20010021500 Correction of genetic defects using chemical chaperones |
| 09/13/2001 | US20010021403 Gastrointestinal disorders |
| 09/13/2001 | US20010021397 Solvent extraction from yeast |
| 09/13/2001 | US20010021395 Mixture of nucleic acid and anticancer agent |
| 09/13/2001 | US20010021392 Such as ibuprofen |
| 09/13/2001 | US20010021388 Cyclization of a triether with a diamine compound |
| 09/13/2001 | US20010021373 Coated chewing gum products containing an acid blocker |
| 09/13/2001 | US20010021370 Parasiticides, antiprotozoa agent |
| 09/13/2001 | US20010021367 Process for the extraction of a compound by a fluorocarbon compound |
| 09/13/2001 | DE10108097A1 Cosmetic formulation, especially for use on aging and/or stressed skin, contains trimethylammonium-methyl compound, metabolite and/or S-adenosylmethionine besides water and substance forming lamellar structures with water |
| 09/13/2001 | DE10106530A1 Medicament for eliminating toxic agents derived from infected animal feed from the body, comprises uridine diphosphate glucuronic acid, forming water-soluble, inactive conjugates with the toxic agents |
| 09/13/2001 | DE10011081A1 Lacquer formulation for treating and preventing onychomycosis, comprising combination of systemic and topical antimycotic agents in film-forming polymer base |
| 09/13/2001 | DE10011032A1 Stable solutions of acetylsalicylic acid in mixture of organic solvent and water, useful for topical treatment of pain, especially pain associated with herpes zoster |
| 09/13/2001 | DE10010512A1 Non-toxic antimicrobial agent for controlling Pseudomonas aeruginosa, comprising hydroxychavicol, especially used as disinfectant, preservative or drug for topical or oral administration |
| 09/13/2001 | CA2413923A1 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
| 09/13/2001 | CA2402602A1 Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides |
| 09/13/2001 | CA2402466A1 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | CA2402433A1 Compounds for pdt |
| 09/13/2001 | CA2402345A1 Azole compounds as therapeutic agents for fungal infections |
| 09/13/2001 | CA2402341A1 Metabotropic glutamate receptor antagonists for treating tolerance and dependency |
| 09/13/2001 | CA2402315A1 Therapeutic uses of ppar mediators |
| 09/13/2001 | CA2402273A1 Methods and compositions for dietary supplements |
| 09/13/2001 | CA2402179A1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | CA2402174A1 Indole derivatives, process for preparation of the same and use thereof |
| 09/13/2001 | CA2402096A1 Vasoactive agents |
| 09/13/2001 | CA2402039A1 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 09/13/2001 | CA2402027A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | CA2401953A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 09/13/2001 | CA2401857A1 New self emulsifying drug delivery system |
| 09/13/2001 | CA2401706A1 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 09/13/2001 | CA2401524A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2401055A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2400571A1 Treatment of psoriasis |
| 09/13/2001 | CA2400527A1 Urease inhibitors |
| 09/13/2001 | CA2400415A1 Nucleic acid sensor molecules |
| 09/13/2001 | CA2399921A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399913A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399111A1 New aza-indolyl derivatives |